Our firm is about people. That is our motto and that will always be our reality.
We do our best to get to know our clients, understand their situations, and get them the compensation they deserve.
At TorHoerman Law, we believe that if we continue to focus on the people that we represent, and continue to be true to the people that we are – justice will always be served.
Without our team, we would’nt be able to provide our clients with anything close to the level of service they receive when they work with us.
The TorHoerman Law Team commits to the sincere belief that those injured by the misconduct of others, especially large corporate profit mongers, deserve justice for their injuries.
Our team is what has made TorHoerman Law a very special place since 2009.
TorHoerman Law will take a Sterigenics Ethylene Oxide Exposure case to trial in Atlanta, Georgia, in March 2026.
The plaintiff in the upcoming trial is a Cobb County resident who lived near the facility and was unknowingly exposed to EtO emissions over the course of several years.
This case is part of a broader national effort to hold Sterigenics accountable for environmental contamination and resulting injuries in multiple communities.
Ethylene Oxide Lawsuit claims center on allegations that Sterigenics U.S., LLC and other defendants negligently released hazardous levels of ethylene oxide (EtO), exposing nearby residents and workers to a known carcinogen linked to breast cancer, leukemia, lymphoma, and other serious illnesses.
TorHoerman Law is actively accepting new clients for the Ethylene Oxide Lawsuit.
On this page, we’ll discuss the basis of the Ethylene Oxide Lawsuit, facilities in the United States known to release ethylene oxide emissions, the health risks of exposure to ethylene oxide, past lawsuits filed by those who have inhaled ethylene oxide and suffered health effects, and much more.
Medical sterilization facilities responsible for sanitizing equipment across the United States are emitting a known human carcinogen, Ethylene Oxide (EtO), into surrounding communities.
The Environmental Protection Agency (EPA) has classified ethylene oxide as a Group 1 human carcinogen, meaning there is clear evidence linking exposure to cancer in humans.
Used primarily to sterilize medical instruments and certain food products, EtO is a hazardous air pollutant that poses significant health risks when released into the air.
Inhalation exposure to EtO has been linked to breast cancer, leukemia (ALL, AML, CLL, and Hairy Cell Leukemia), Hodgkin lymphoma, multiple myeloma, and various types of non-Hodgkin lymphoma.
Communities living near facilities that use EtO face an elevated cancer risk, particularly when emissions are not properly controlled.
Studies have shown that long-term exposure increases the likelihood of genetic mutations, cellular damage, and tumor development.
Many affected individuals were unknowingly exposed to ethylene oxide for years, unaware of the serious health consequences.
Lawsuits are now being investigated and filed against Sterigenics and other companies to hold them accountable for negligent releases of these chemicals, seeking compensation for victims suffering from life-altering diagnoses.
TorHoerman Law is accepting new clients for the Ethylene Oxide Exposure Lawsuit.
If you or a loved one were diagnosed with cancer or other serious health problems associated with exposure to ethylene oxide and lived near a facility with known emissions, you may be eligible to file an Ethylene Oxide Lawsuit and seek financial compensation.
Contact TorHoerman Law today for a free consultation.
Use the chat feature on this page to find out if you qualify for an Ethylene Oxide Lawsuit instantly.
Virginia regulators report that a faulty check valve at a Sterilization Services of Virginia facility in Henrico County released approximately 580 pounds of ethylene oxide during a single incident on April 9.
According to the Virginia Department of Environmental Quality, the release exceeded the facility’s annual permitted emissions limit in a single day.
State regulators later issued a notice of violation and imposed a $53,000 fine.
The incident has renewed attention on concerns surrounding ethylene oxide emissions from medical sterilization facilities.
Regulators say the company has replaced the failed equipment and implemented additional monitoring measures to prevent similar releases.
The event comes as communities across the country continue to pursue lawsuits involving ethylene oxide emissions.
Plaintiffs allege that long-term exposure to the chemical increased their risk of developing cancer and other serious health conditions.
Ethylene oxide litigation remains active in certain communities across the country, with plaintiffs seeking compensation for alleged injuries linked to emissions from sterilization plants.
June 15, 2026: Pennsylvania Court Fight Could Shape Future of Ethylene Oxide Litigation
A developing legal dispute in Pennsylvania could influence how courts handle ethylene oxide exposure claims, particularly cases seeking medical monitoring for residents living near sterilization facilities.
The issue stems from litigation against B. Braun’s medical device sterilization facility in Allentown, Pennsylvania.
In late 2025, a Lehigh County judge denied class certification in a lawsuit that sought to establish a medical monitoring program for residents who alleged exposure to ethylene oxide emissions.
The court found that the proposed class failed to meet Pennsylvania’s requirements for class actions and questioned the reliability of several expert opinions offered by the plaintiffs.
The ruling prevented the case from proceeding as a class action and limited plaintiffs to pursuing individual claims.
The proposed class would have included residents living near the facility who sought court ordered medical monitoring based on alleged increased health risks from exposure to ethylene oxide, a chemical used to sterilize medical devices and classified by the U.S. Environmental Protection Agency as a carcinogen.
Legal observers are closely watching the case because it raises broader questions about the standards required to certify medical monitoring classes in environmental exposure litigation.
The outcome could affect future ethylene oxide lawsuits in Pennsylvania and potentially influence similar claims involving exposure to industrial emissions.
The dispute comes as ethylene oxide litigation continues nationwide.
Courts across the country are evaluating claims involving alleged cancer risks from long term exposure to emissions from sterilization facilities, with plaintiffs pursuing personal injury and medical monitoring claims while defendants challenge causation and class certification efforts.
Virginia regulators are seeking enforcement action against Sterilization Services of Virginia after the Henrico facility released approximately 580 pounds of ethylene oxide (EtO) into the air on April 9 due to a faulty check valve.
According to a proposed consent order from the Virginia Department of Environmental Quality (DEQ), the release exceeded the facility’s annual permitted emissions limit and resulted in multiple cited violations, including failures of required pollution-control operations.
The incident has renewed concerns among local residents and environmental groups, particularly because community members and local officials were not informed until months after the release.
Henrico County officials criticized the lack of direct notification, while advocacy groups argued that residents living near the facility should have been alerted given the volume of EtO released.
DEQ maintains it followed federal reporting requirements and noted that public notifications are typically handled by local emergency officials when there is an immediate threat to public safety.
As part of the proposed settlement, Sterilization Services of Virginia agreed to corrective actions and a $54,000 civil penalty. The release comes amid ongoing national debate over ethylene oxide regulation.
While the EPA adopted stricter emissions standards in 2024 to significantly reduce EtO emissions from sterilization facilities, implementation deadlines were later extended for some operators.
DEQ officials noted that the Henrico facility installed additional emissions-control equipment in 2025 to meet upcoming federal requirements.
Public comments on the proposed enforcement action remain open through June 19.
Ethylene oxide litigation in California reached a significant milestone in May after a judge denied attempts by Sterigenics to block claims brought by residents living near its Vernon sterilization facility.
The lawsuit, filed by Southeast Los Angeles residents, alleges the company exposed surrounding communities to unsafe levels of ethylene oxide for decades without adequately warning the public about the cancer risks associated with the toxic gas.
The ruling allows the plaintiffs’ claims to move closer to trial and increases pressure on the company to defend allegations that long-term emissions contributed to elevated cancer risks in nearby neighborhoods.
The decision comes amid growing nationwide scrutiny of ethylene oxide emissions from commercial sterilization facilities.
Plaintiffs are seeking damages and stronger safeguards, including stricter emissions controls, real-time reporting, and enhanced regulatory oversight.
As courts continue to weigh claims involving long-term community exposure, the Vernon case is expected to be closely watched as another major test of liability surrounding ethylene oxide emissions and alleged cancer injuries.
May 14th, 2026: Georgia Appeals Court Reviews $20 Million Verdict in Ethylene Oxide Cancer Lawsuit
A Georgia appellate court is considering whether to uphold a $20 million compensatory damages verdict in an Ethylene Oxide Lawsuit involving allegations that long-term exposure to ethylene oxide caused non-Hodgkin lymphoma.
The Georgia Court of Appeals heard arguments from attorneys representing Becton Dickinson and its subsidiary C. R. Bard regarding whether a mistrial on punitive damages requires an entirely new trial.
The litigation stems from a 2021 lawsuit filed by former Bard worker Gary Walker, who alleged that decades of exposure to ethylene oxide emissions from the companies’ Covington, Georgia sterilization facility caused his cancer.
Ethylene oxide is a chemical used to sterilize medical devices and has been linked to elevated cancer risks in multiple lawsuits filed across Georgia and other states.
A Gwinnett County jury awarded Walker $20 million in compensatory damages during a 2025 trial.
Jurors also issued a $50 million punitive damages award after finding Bard acted with specific intent.
Judge Emily Brantley later declared a mistrial on punitive damages after one juror stated she did not agree with the finding regarding specific intent.
Defense attorneys argued before the appellate court that the mistrial created an incomplete verdict requiring a full retrial.
Attorneys for Bard stated that separate juries should not decide compensatory and punitive damages independently and then combine the outcomes into one judgment.
Walker’s attorneys argued that Georgia appellate courts have previously allowed partial verdicts to remain intact under similar circumstances.
Plaintiff counsel also argued that Georgia’s 2025 changes governing bifurcated trials do not apply because Bard did not invoke the statute before trial.
The appeal also focuses on allegations that plaintiff attorneys improperly referenced Bard’s annual facility earnings during arguments about damages.
Defense attorneys claimed the statements improperly influenced the jury by introducing punitive damages concepts during the compensatory phase of trial.
New lawsuits continue to emerge over ethylene oxide emissions from a former sterilization facility in Temple Terrace, Florida, after investigators found the plant released the toxic gas into nearby neighborhoods for years without adequate emission controls.
According to a recent Tampa Bay Times investigation, American Contract Systems used ethylene oxide to sterilize medical equipment at the facility while venting the carcinogenic gas into the surrounding community without filters that could have significantly reduced emissions.
The report indicates regulators initially failed to require stricter controls due to gaps and ambiguities in federal rules governing certain sterilization methods.
Ethylene oxide is widely used to sterilize medical devices that cannot withstand steam cleaning or high heat.
However, the gas has been linked to increased risks of cancer, neurological damage and respiratory problems following prolonged exposure.
In 2023, the EPA updated its assessment of ethylene oxide risks and determined that cancer risks for residents living near the Temple Terrace plant were up to 40 times higher than what is generally considered acceptable.
Many nearby residents reportedly did not know the facility was emitting the gas until the EPA findings became public.
The fallout has led to more than a dozen lawsuits against American Contract Systems and BayCare, which owned the building where the sterilization operations took place.
Plaintiffs allege the companies exposed surrounding communities to dangerous levels of ethylene oxide and caused serious illnesses, including cancer.
The defendants have denied liability and sought dismissal of certain claims.
The Florida lawsuits mirror similar ethylene oxide litigation filed nationwide involving sterilization facilities in Illinois, Georgia, Michigan, Texas, Ohio and Pennsylvania.
Many of those cases also involve allegations that companies failed to properly control emissions despite growing evidence linking long-term exposure to elevated cancer risks.
American Contract Systems has since shut down the Temple Terrace operation after regulators issued fines related to failures involving emission filters, required sampling and reporting obligations.
The litigation also comes as the EPA considers rolling back portions of stricter ethylene oxide emission rules adopted in 2024, including requirements involving continuous monitoring and certain filtration standards.
Critics argue the proposed changes could weaken protections for communities located near sterilization plants across the country.
The EPA has extended the public comment period on its proposed rollback of key ethylene oxide emissions standards, signaling that the agency is continuing to reconsider major restrictions adopted in 2024 for commercial sterilization facilities.
The proposed revisions would weaken several monitoring and containment requirements that were originally implemented after years of litigation and community complaints involving cancer risks tied to ethylene oxide exposure.
Specifically, the EPA is considering removing mandatory “total enclosure” requirements designed to fully capture emissions, easing standards for aeration room vents, and allowing facilities to choose less stringent monitoring methods instead of continuous emissions tracking.
The agency argues the changes are necessary because the 2024 rules imposed significant compliance costs on sterilization facilities and threatened supply chains for medical devices and pharmaceuticals.
According to the EPA, the revised approach could save affected industries tens of millions of dollars annually through 2046.
The rollback effort is significant for the ongoing ethylene oxide litigation.
Plaintiffs in lawsuits against sterilization companies have relied heavily on stricter federal standards to argue that facilities failed to adequately control toxic emissions linked to cancers such as non-Hodgkin’s lymphoma and breast cancer.
If the EPA rescinds portions of those rules, defendants may attempt to use the revised standards to argue that prior emissions controls were reasonable or consistent with regulatory expectations at the time.
At the same time, the agency’s decision to revisit the rules does not erase past verdicts or settlements tied to ethylene oxide exposure.
Courts have already seen substantial jury awards and large settlements involving claims that sterilization facilities released dangerous levels of the gas into surrounding communities for years.
As public comments continue through May 15, the outcome of the EPA’s reconsideration could play an important role in shaping future regulatory and litigation battles over ethylene oxide emissions.
Federal regulators are taking a step back from recently tightened ethylene oxide (EtO) emissions standards.
The U.S. Environmental Protection Agency is now reconsidering its 2024 rules, which had imposed stricter limits on emissions from sterilization facilities, and will discuss possible changes during an April 16, 2026 regulatory roundtable.
Ethylene oxide is a gas used to sterilize medical equipment, but it has also been linked to increased cancer risks in nearby communities.
The 2024 rules were designed to reduce exposure by requiring facilities to monitor emissions more closely and limit the release of the gas.
Now, regulators are revisiting those requirements after concerns that the stricter standards could force sterilization facilities, especially smaller operators, out of the market and disrupt the supply of critical medical devices.
The U.S. Environmental Protection Agency is proposing to roll back major ethylene oxide safety requirements put in place in 2024, a move that could become a central issue in ongoing toxic-exposure litigation.
The proposed rule would eliminate or weaken several protections, including requirements for continuous emissions monitoring and stricter controls in aeration rooms: areas where ethylene oxide gas is released after sterilization.
Regulators say the current standards are too difficult for facilities to meet and could disrupt the medical supply chain.
These protections were originally introduced after multiple toxic gas leaks in 2019 led to shutdowns at sterilization facilities and raised concerns about long-term exposure risks.
Ethylene oxide has been linked to serious health effects, including cancers such as Non-Hodgkin lymphoma.
The rollback comes as companies like Sterigenics and C. R. Bard continue to face lawsuits from individuals who allege they developed cancer after prolonged exposure to emissions from nearby facilities.
Prior litigation has already resulted in significant outcomes, including a $408 million settlement and a $20 million jury verdict in a single-plaintiff case.
From a litigation standpoint, the proposed changes could influence how courts evaluate safety standards and corporate responsibility.
Plaintiffs may argue that loosening monitoring and emission controls increases the risk of harmful exposure, while defendants may rely on the revised regulations to argue compliance with federal standards.
As the EPA opens a public comment period on the proposal, the evolving regulatory landscape is expected to play a key role in shaping future ethylene oxide lawsuits and how exposure claims are argued in court.
A proposed regulatory change involving ethylene oxide emissions has renewed scrutiny of the chemical’s health risks and may influence ongoing Ethylene Oxide Lawsuits filed by individuals who allege long-term exposure contributed to cancer diagnoses.
The proposal from the U.S. Environmental Protection Agency would rescind portions of emission standards adopted in 2024 that targeted pollution from facilities using ethylene oxide to sterilize medical equipment.
The proposed rule would eliminate requirements designed to reduce ethylene oxide emissions by roughly 90 percent. Ethylene oxide is widely used to sterilize heat-sensitive medical devices, including surgical equipment, pacemakers, and heart valves.
The agency cited the importance of maintaining a stable supply chain for sterilized medical products as a factor in reconsidering the earlier regulatory framework.
The proposal would remove several provisions adopted during the previous administration that were based on updated risk assessments evaluating the health impacts of ethylene oxide exposure. Earlier agency research identified the chemical as significantly more carcinogenic than previously understood.
A 2016 assessment by the Environmental Protection Agency concluded that ethylene oxide may be approximately thirty times more carcinogenic for adults than earlier estimates indicated.
The new proposal would also eliminate several monitoring and containment requirements imposed on commercial sterilization facilities. Facilities would no longer be required to operate continuous emissions monitoring systems to demonstrate compliance with regulatory limits.
The proposed rule also removes requirements that facilities fully enclose sterilization operations to prevent ethylene oxide from escaping through open warehouse doors or other uncontrolled openings.
A closely watched lawsuit involving alleged cancer caused by ethylene oxide (EtO) emissions from a medical sterilization facility has settled shortly before the case was set to go to the jury.
The case, filed in Colorado state court, involved claims that toxic ethylene oxide gas released from a medical equipment sterilization plant operated by Terumo caused a man to develop a rare form of cancer.
After several weeks of testimony, the parties informed the court on February 18 that they had reached a confidential settlement just before closing arguments were scheduled to begin.
During the trial, the plaintiff alleged that the facility released ethylene oxide into nearby residential areas for years due to inadequate exhaust filtration systems.
Attorneys argued that long-term exposure to the sterilizing gas led to the development of cancer, comparing the litigation to other historic toxic torts such as asbestos and tobacco cases.
Ethylene oxide is widely used to sterilize medical equipment that cannot withstand high-temperature sterilization processes.
However, plaintiffs in these lawsuits argue the gas poses serious health risks because it is colorless, odorless, and tasteless, making exposure difficult to detect while emissions may continue for years.
The defense maintained throughout the trial that any emissions from the facility were too low to cause illness and argued the company complied with applicable environmental and industry regulations.
Although the settlement amount was not disclosed, the case is part of a broader wave of ethylene oxide lawsuits filed by individuals living near sterilization plants who claim long-term exposure to the chemical contributed to cancer diagnoses.
Previous trials involving similar allegations have produced mixed results, including both defense verdicts and multimillion-dollar jury awards, suggesting the litigation remains highly contested as more cases move toward trial.
The Illinois Supreme Court has issued a significant ruling that may affect coverage disputes tied to ethylene oxide litigation.
In Griffith Foods International, Inc. v. National Union Fire Insurance Company of Pittsburgh (2026 IL 131710), the court held that regulatory approval to emit pollution does not prevent an insurer from invoking a pollution exclusion in a commercial general liability (CGL) policy.
The insurance dispute arose from underlying mass tort claims involving emissions of ethylene oxide (EtO) from a medical sterilization facility in Willowbrook, Illinois.
Residents alleged that the facility emitted EtO for more than 35 years, contributing to cancer and other illnesses.
The insured companies sought coverage under two CGL policies issued between 1983 and 1985.
However, the policies contained a standard pollution exclusion, which bars coverage for bodily injury arising from the release of contaminants, vapors, fumes, or waste into the atmosphere.
A federal district court initially sided with the insureds, reasoning that because the emissions were made pursuant to an Illinois EPA permit, they arguably did not qualify as excluded “pollution.”
The issue was eventually certified to the Illinois Supreme Court.
The Illinois Supreme Court reversed course and held:
The court emphasized that the exclusion language makes no distinction between permitted and unpermitted emissions.
It also reasoned that allowing coverage simply because emissions were permitted would undermine the purpose of pollution exclusions.
In doing so, the court overruled prior Illinois appellate decisions that had treated regulatory authorization as potentially creating ambiguity.
Environmental groups have filed a federal lawsuit that could influence ongoing Ethylene Oxide lawsuits and public scrutiny over emissions from medical sterilization facilities.
The lawsuit challenges Environmental Protection Agency waivers that allow certain companies to bypass 2024 federal standards designed to reduce cancer risks linked to ethylene oxide exposure.
According to reporting on the lawsuit, Charlotte-based CleanAIRE NC joined other plaintiffs in filing the case in the U.S. District Court for the District of Columbia.
The lawsuit seeks to block two-year renewable exemptions granted to 40 sterilization facilities nationwide.
Ethylene oxide is a chemical used to sterilize medical equipment and is classified as a carcinogen.
Federal regulators strengthened emissions rules in 2024 after research indicated the chemical is far more toxic than earlier estimates.
The 2024 standards targeted a reduction in cancer risk for residents living near commercial sterilization plants.
Plaintiffs allege that several facilities receiving exemptions already had the capability to meet the updated standards.
The lawsuit argues that the Environmental Protection Agency exceeded its authority by issuing broad waivers through a presidential exemption process under the Clean Air Act.
The plaintiffs also state that safer sterilization alternatives exist and can operate without increasing costs.
Sterigenics, an Illinois-based sterilization company named in public reporting, operates a facility near residential communities in Charlotte.
Advocacy groups state that many exempted facilities are located near low-income neighborhoods with large Black and brown populations.
The lawsuit frames the exemptions as a public health issue tied to long-standing concerns about environmental exposure and cancer risk, which form the basis of many Ethylene Oxide lawsuits filed across the country.
Courts handling ethylene oxide litigation are closely reviewing whether defendants’ emissions and air-dispersion models accurately estimate long-term exposure in surrounding neighborhoods.
Plaintiffs are challenging key modeling inputs, including stack height, wind patterns, and facility operating hours, arguing those assumptions materially affect projected cancer risk levels.
A central dispute involves testing duration.
Plaintiffs contend that short-term air sampling fails to capture cumulative exposure from continuous emissions over years or decades.
Defendants argue that limited testing periods provide a reliable basis for estimating long-term risk.
Judges are now deciding which modeling methods can reliably convert emissions data into neighborhood-level exposure estimates.
Those rulings matter because emissions modeling is central to proving causation in ethylene oxide cases, and expert admissibility decisions often determine whether claims survive
Environmental organizations have filed a federal lawsuit that could influence ongoing Ethylene Oxide Lawsuits involving cancer risks tied to sterilization facilities.
The complaint targets a Trump administration decision that paused federal emissions standards for certain medical device sterilizers that use ethylene oxide (EtO), a chemical classified as a carcinogen.
The Southern Environmental Law Center and the Natural Resources Defense Council filed the complaint in the U.S. District Court for the District of Columbia on behalf of nonprofits in North Carolina, Georgia, and Virginia. The lawsuit names President Donald Trump, the Environmental Protection Agency (EPA), and EPA Administrator Lee Zeldin as defendants.
Ethylene oxide sterilizes about half of all medical devices used in the United States. The EPA has linked long-term exposure to elevated cancer risk for communities located near sterilization plants.
EPA analysis estimated that 8.5 million people live in areas facing increased lifetime cancer risk tied to emissions from commercial sterilizers. The agency reported that some facilities created a cancer risk level 60 times higher than its threshold for unacceptable exposure.
In 2024, the EPA finalized a rule designed to reduce EtO emissions by about 21 tons per year. The rule imposed new standards on building leaks, chamber exhaust vents, and smaller facilities that previously faced limited regulation.
A 2025 presidential proclamation delayed enforcement of the rule for 40 sterilization facilities for two years while the EPA reconsiders the standards.
The complaint states that the proclamation covers about 45% of commercial sterilizers and allows facilities to avoid stricter emissions controls and reporting requirements.
The lawsuit argues that the Clean Air Act permits temporary exemptions only when required technology is unavailable and when national security interests are involved.
Plaintiffs state that no president had used the exemption authority in the 55 years since Congress enacted the provision. The complaint asserts that many exempted facilities already use available technology capable of meeting the standards.
Plaintiffs request a court order declaring the proclamation invalid and directing the EPA to enforce compliance deadlines in the 2024 rule.
A federal jury has begun hearing opening statements in a high-stakes trial over alleged health harms linked to ethylene oxide gas exposure in Colorado.
The case centers on claims that companies employing ethylene oxide in sterilization and manufacturing processes failed to adequately warn workers and nearby residents about the risks of exposure to the gas, which is classified as a human carcinogen by multiple health agencies.
Plaintiffs’ attorneys told jurors in opening arguments that defendants knew or should have known of the chemical’s dangers and yet did not implement sufficient safety measures, monitoring, or warnings to protect those exposed on the job or in surrounding communities.
They contend that long-term exposure can lead to serious health conditions, including cancer and other chronic diseases.
Defense counsel, in contrast, emphasized regulatory compliance and questioned whether the scientific evidence presented will support a causal link between the exposures alleged and the plaintiffs’ injuries.
The trial is expected to feature dueling expert testimony on toxicology, exposure assessment, and industry standards for hazard communication.
From a litigation standpoint, this trial reflects a broader trend in toxic exposure cases where juries are being asked to weigh complex scientific evidence about environmental and occupational hazards.
Similar cases often hinge on whether defendants provided adequate warnings and took reasonable steps to mitigate foreseeable risk, and decisions in this case may influence the posture of future ethylene oxide and other industrial chemical lawsuits nationwide.
January 27, 2026: Federal Agencies Highlight Continued Risks from Ethylene Oxide Exposure
Employees working in U.S. sterilization facilities, medical supply warehouses, and industrial operations remain at significant risk from ethylene oxide, a chemical used to sterilize medical equipment.
The Environmental Protection Agency has classified ethylene oxide as a known human carcinogen and recently adopted stricter controls aimed at reducing emissions by 90 percent.
The agency also signaled plans to lower allowable workplace exposure levels to 0.1 parts per million by 2035, citing evidence that the chemical may be up to 60 times more dangerous than previously estimated.
Despite these updates, OSHA has not revised its worker exposure limits since 1984, leaving employees at sterilization facilities exposed to concentrations ten times higher than what modern science now recommends.
Long-term exposure has been linked to cancers, including leukemia, non-Hodgkin lymphoma, multiple myeloma, and breast cancer, while short-term exposure can trigger respiratory and neurological symptoms.
Communities near facilities in Illinois, Texas, Missouri, and California have faced elevated cancer risks, in some cases exceeding federal thresholds by more than tenfold.
The gap between OSHA’s outdated standards and EPA’s current assessments has raised concerns about worker safety and environmental justice.
Experts advocate for real-time emissions monitoring, enhanced ventilation and leak detection systems, comprehensive protective equipment, and regular medical evaluations to safeguard employees.
The Environmental Protection Agency (EPA) has come under scrutiny for gaps in its regulation of ethylene oxide (EtO), a chemical widely used in medical sterilization and other industrial processes, leaving workers at elevated risk of cancer.
Recent reporting by The Lens highlights that these regulatory “blind spots” allow some facilities to operate without full emissions controls, potentially exposing employees to long-term health hazards.
Ethylene oxide is classified as a human carcinogen, linked to leukemia, lymphoma, breast cancer, and other malignancies.
Workers in Louisiana’s industrial corridor, producing roughly 20% of the U.S. EtO emissions, are among the most affected, though exposure risks extend nationwide.
Long-term inhalation can raise lifetime cancer risk significantly, with studies indicating that chronic exposure may increase certain cancer risks by up to 60 times.
EPA enforcement has historically been uneven, with exemptions and delayed implementation of updated emission standards leaving gaps in workplace protections.
While OSHA maintains standards requiring labeling, hazard communication, and protective equipment, critics argue that these rules lag behind current research on EtO’s cancer risks.
Communities surrounding EtO-emitting facilities also face elevated risk, as documented in multiple reports from industrial areas in Georgia, Louisiana, Colorado, and Puerto Rico.
Public health authorities and independent researchers have repeatedly urged stronger safeguards and more consistent oversight to reduce both worker and community exposure.
The ongoing concerns over ethylene oxide underscore a potential area for litigation involving occupational exposure, regulatory compliance, and employer liability for preventable cancer risks.
A Pennsylvania court has denied class action certification in an ethylene oxide lawsuit involving emissions from B. Braun’s medical device sterilization facility in Hanover Township, Lehigh County.
The ruling limits the case to individual claims rather than allowing it to proceed on behalf of a broader community seeking medical monitoring.
The lawsuit was filed by a nearby resident who alleged long-term exposure to ethylene oxide (EtO) emissions from B. Braun’s plant at 901 Marcon Boulevard, outside Allentown. The complaint claimed that EtO exposure placed surrounding residents at an increased risk of developing cancer and sought class action status to establish a court-supervised medical monitoring program.
Ethylene oxide is used to sterilize medical devices and is classified by the U.S. Environmental Protection Agency as a human carcinogen.
The plaintiff argued that prolonged exposure to EtO emissions warranted periodic diagnostic testing for thousands of residents living near the facility over more than three decades.
In a 49-page decision issued December 31, the Lehigh County Court of Common Pleas concluded that the plaintiff failed to satisfy four of the five requirements for class certification under Pennsylvania law.
While the court found that the plaintiff’s claims were typical of others who might be included in a proposed class, it ruled that the remaining criteria were not met.
The court cited several deficiencies, including a lack of credible evidence establishing the size of the proposed class.
One expert witness testified that more than 22,000 people may have been exposed to elevated EtO levels between 1991 and 2024, but the court found the expert’s testimony and opinions not credible.
Ethylene oxide lawsuits involving Sterigenics are increasingly shaped by court rulings addressing whether insurers must cover defense costs tied to emissions-based cancer claims.
Recent decisions emphasize how companies modeled and disclosed ethylene oxide exposure can affect not only liability, but also whether insurance policies trigger a duty to defend.
The issue gained clarity after the United States Court of Appeals for the Third Circuit ruled that B. Braun must pay its own legal defense costs in ethylene oxide lawsuits tied to emissions near its facility.
The court agreed with lower rulings that policy exclusions applied to claims alleging long-term chemical exposure, limiting insurer responsibility even at early litigation stages.
That ruling matters for Sterigenics ethylene oxide lawsuits because defense-cost coverage often turns on how exposure allegations are framed.
Courts reviewing duty-to-defend disputes are examining whether emissions modeling, cancer risk assessments, and internal exposure analyses place claims inside or outside standard pollution exclusions.
Plaintiffs in Sterigenics ethylene oxide litigation continue to seek internal emissions data and consultant reports, records that may influence both liability findings and insurance coverage determinations.
As duty-to-defend arguments develop, insurance rulings remain a narrow but consequential pressure point in ongoing Sterigenics ethylene oxide lawsuits and related EtO cancer claims.
TorHoerman Law is actively accepting new clients for the EtO exposure cases near the Sterigenics facility in Smyrna/Atlanta.
Reach out to us for a free consultation.
Use the chat feature on this page to find out if you qualify and to speak with our team of ethylene oxide exposure lawyers.
Colorado air regulators voted Thursday to move forward with an April rulemaking hearing that will set the state’s first emissions controls for key toxic air contaminants, including ethylene oxide.
While the broader rulemaking addresses five pollutants, ethylene oxide remains a key focus due to its well-documented cancer risk and its use at medical device sterilization facilities close to residential areas.
For ethylene oxide, the Air Pollution Control Division intends to broadly align state requirements with new federal standards finalized last year.
These rules would apply to three medical device sterilization facilities in Colorado, including Terumo BCT in Lakewood.
Regulators stated the approach lets the state act swiftly on ethylene oxide controls while preventing redundant requirements.
However, it also restricts Colorado’s capacity to enforce stricter, location-specific measures at this stage.
Commission members emphasized that enforcement will focus on facilities in communities disproportionately affected and in areas where modeled cancer risk from toxic air contaminants exceeds 20 excess cases per million people.
While the commission chose not to tie the new toxic air standards to permitting requirements for now, it left open the possibility of future legislation that could expand state authority over ethylene oxide and other hazardous air pollutants.
The April hearing will decide whether the proposed controls are sufficient to lower long-term cancer risks linked to ethylene oxide exposure.
A lawsuit filed in Kanawha County, West Virginia, alleges that prolonged ethylene oxide (EtO) emissions from multiple industrial sites created a dangerous concentration of cancer-causing air pollution in the Kanawha Valley.
EtO is a known human carcinogen used in chemical manufacturing and medical sterilization.
The suit is brought on behalf of residents like Cathy Flint, who developed incurable cancer after decades of living less than 500 feet from a permitted chemical plant.
Plaintiffs argue that while each facility may have individually complied with EPA limits, the cumulative impact of all emissions has significantly elevated cancer risks in the area, up to 300 cases per 1 million, far beyond the EPA’s acceptable threshold of 1-in-1 million.
Defendants, including Union Carbide and over a dozen other companies and institutions, deny liability, citing compliance with prevailing safety standards and asserting they cannot be held responsible for emissions from other entities.
The case is ongoing, with over 20,000 pages of legal documents already filed.
Plaintiffs seek to compel regulators to consider cumulative emissions in air quality assessments and require real-time monitoring for EtO exposure.
The Illinois Supreme Court is reviewing whether ethylene oxide emissions permitted under state environmental laws should be exempt from “pollution exclusions” in commercial general liability (CGL) insurance policies.
The case stems from Sterigenics and its former parent company, Griffith Foods’ request for $150 million in insurance coverage for defense costs arising from hundreds of lawsuits tied to emissions from their Willowbrook, Illinois, sterilization facility.
At issue is whether emissions authorized by state permits still constitute “traditional environmental pollution” under Illinois law.
Sterigenics argues that legally permitted emissions fall outside the policy’s pollution exclusion, citing the Illinois Environmental Protection Act, which does not define regulated emissions as pollution.
Attorneys for Sterigenics claim the company’s medical device sterilization operations were “pro-social” and fully cleared by the Illinois EPA.
They maintain that the exclusion should not apply when the government explicitly authorizes emissions.
In contrast, National Union Fire Insurance Co. contends that the pollution exclusion clearly bars coverage for toxic gas discharges, regardless of whether permitting is required.
They warn that accepting Sterigenics’ argument would effectively nullify pollution exclusions across the industry, since most industrial polluters operate under some form of regulation.
The Seventh Circuit referred the case to the Illinois high court for guidance, citing ambiguity in how prior case law applies.
The outcome may set a national precedent on whether regulatory permits override standard pollution exclusions in insurance policies.
The case is Griffith Foods International Inc. et al. v. National Union Fire Insurance Co. of Pittsburgh, Pa., No. 131710, in the Supreme Court of Illinois.
The Georgia Court of Appeals has vacated a lower court ruling that dismissed eight bellwether toxic tort suits alleging harmful emissions from the Sterigenics sterilization plant in Smyrna caused cancer and birth defects.
The appellate panel found the trial court misapplied the Eleventh Circuit’s standard for expert testimony in toxic exposure cases under McClain v. Metabolife International, Inc., using a “third way” test not recognized by federal precedent.
According to the ruling, the trial court improperly excluded two experts who testified that exposure to “above background” levels of ethylene oxide could increase cancer and birth defect risks.
The appellate judges clarified that McClain requires courts to classify toxins into one of two categories (those widely accepted as harmful and those requiring rigorous proof of general causation) rather than creating new evidentiary standards.
The panel ordered the case back to the trial court to determine which category ethylene oxide falls under and to reassess the reliability of the experts’ methodologies, including whether causation can be shown through epidemiological or background-risk evidence.
The lawsuits, brought by residents near the Smyrna plant, accuse Sterigenics and its parent company Sotera Health LLC of releasing ethylene oxide emissions over decades, allegedly causing cancers and birth defects in nearby communities.
The appellate decision reopens the door for plaintiffs to present expert evidence at trial, marking a key procedural victory in one of Georgia’s most closely watched environmental contamination cases.
TorHoerman Law is actively accepting new clients for the EtO exposure cases near the Sterigenics facility in Smyrna/Atlanta.
Reach out to us for a free consultation.
Use the chat feature on this page to find out if you qualify and to speak with our team of ethylene oxide exposure lawyers.
Communities near sterilization plants are pushing back after the federal government granted exemptions to new EPA rules meant to cut ethylene oxide (EtO) emissions by 90%.
These waivers include the Sterigenics facility in Smyrna, Georgia—despite the company already meeting the stricter standards.
EtO is a known carcinogen.
For decades, facilities like Sterigenics released it into neighborhoods without public awareness.
In 2018, EPA data flagged the Smyrna area as having one of the nation’s highest cancer risks due to EtO.
Residents organized. Georgia passed state laws requiring more reporting.
But enforcement still relies heavily on company self-reporting.
The state does not conduct regular, independent air testing.
Now, locals are asking: If emissions controls are in place, why seek an exemption? Sterigenics hasn’t answered.
Neither have federal regulators.
Colorado regulators have approved the state’s first health-based air standards for toxic chemicals, including ethylene oxide, formaldehyde, benzene, and hexavalent chromium, marking a significant policy shift toward regulating industrial pollutants linked to cancer and respiratory diseases.
The Air Quality Control Commission voted last week to set exposure limits for five air toxins, after years of pressure from environmental and community groups.
Ethylene oxide, used to sterilize medical devices, has come under increased scrutiny after lawsuits over exposure in Lakewood, where emissions from Terumo Blood and Cell Technologies were linked to higher cancer risks.
While advocates praised the decision as a “solid first step,” they criticized the commissioners for lowering some non-cancer risk levels in response to lobbying from industry groups.
The Colorado Department of Public Health and Environment will spend the next six months developing enforcement protocols and determining how to incorporate the new caps into air permits for affected facilities.
The commission’s standards, which align with a one-in-a-million lifetime cancer risk threshold, will now be submitted to the legislature for approval in December.
Formal emission control rules are expected to be finalized by April 2026, making Colorado one of the first states to set enforceable limits on ethylene oxide and similar toxic air pollutants.
In Covington, Georgia, over 300 residents have filed lawsuits against Becton Dickinson and Company (BD Bard), claiming that decades of ethylene oxide (EtO) emissions from the company’s sterilization plant led to widespread cancer in nearby neighborhoods.
The facility, located less than a mile from homes, schools, and a community baseball field, has been operating in Covington for over 50 years.
Plaintiffs, including several well-known community figures, claim BD’s EtO emissions exposed thousands to unsafe levels of the carcinogenic gas, resulting in diagnoses of breast cancer, lymphoma, and leukemia.
Their attorney, Michael Geoffroy, previously secured a $20 million jury verdict for Covington truck driver Gary Walker, whose non-Hodgkin lymphoma was linked to occupational EtO exposure.
BD is appealing that verdict.
The lawsuits allege BD failed to regulate emissions and safeguard the community, despite evidence that the plant’s EtO levels have significantly surpassed federal safety standards for decades.
BD states it operates safely and that recent upgrades capture over 97 percent of emissions.
Trial dates for the Covington cases are scheduled to start next year.
The litigation represents one of the most notable community actions regarding exposure to EtO to date.
It could establish the tone for similar claims arising in other parts of Georgia and nationwide.
El Paso residents are growing increasingly concerned about toxic emissions from Cardinal Health’s medical product warehouses, following a recent Grist investigation that found ethylene oxide (EtO) levels near the facilities may surpass federal safety limits.
Modeling indicated that nearly 90% of El Paso’s population could face a cancer risk exceeding the EPA’s target of one in a million, with residents living closest to the warehouses facing risks as high as one in 5,000.
Former warehouse worker “Maria,” now 33, was diagnosed with stage 3 triple-negative breast cancer nearly ten years after working at the Cardinal facility.
Without any family history or genetic predisposition, she only learned about the potential EtO exposure after reading the Grist report.
Experts note her diagnosis matches known results of long-term ethylene oxide exposure, though direct causation cannot yet be confirmed.
Residents living near the warehouses on John Phelan Drive report experiencing ongoing dizziness, headaches, and respiratory problems, which heighten concerns about ambient EtO emissions.
Environmental health researchers state that even small, long-term exposures can increase cancer risk, and current state emission standards might fall behind recent toxicology findings.
Cardinal Health has not yet responded to requests for comment.
Texas regulators assert that the company’s operations meet both state and federal air quality standards.
Meanwhile, recent federal efforts to tighten EtO emission controls have stalled under the Trump administration, which granted sterilization facilities a two-year compliance extension, citing economic concerns.
As federal oversight weakens, communities like El Paso join a growing list of areas questioning whether unregulated emissions from sterilization and warehouse operations silently endanger public health.
The Colorado Air Quality Control Commission has established the state’s first health-based exposure limit for ethylene oxide, a chemical commonly used in commercial sterilization and long linked to an increased cancer risk.
The benchmark aims to limit long-term exposure to a level regulators say should reduce cancer risk to one in a million people.
Despite the importance of the new standard, advocates criticized the commission for setting lower thresholds for ethylene oxide’s non-cancer health effects, aligning with proposals supported by business groups.
Environmental groups argued the decision leaves frontline communities, many near sterilization facilities, without proper protections.
The rule will not take effect for at least a year while awaiting legislative approval, and Colorado has yet to specify how the new ethylene oxide limits will be enforced through permitting or monitoring.
On August 18, 2025, the U.S. Court of Appeals for the Fourth Circuit revived a dismissed ethylene oxide (EtO) exposure lawsuit in Sommerville v. Union Carbide Corp.
The panel majority ruled that the plaintiff could proceed with a medical monitoring claim without showing a present physical illness.
The court held that the injury consisted of the EtO exposure itself and the current financial burden of medical testing required to monitor for cancer and other illnesses.
The case involves allegations that Union Carbide Corporation and Covestro LLC emitted EtO from a facility in South Charleston, West Virginia, exposing surrounding residents.
The District Court for the Southern District of West Virginia previously dismissed the case for lack of Article III standing, holding that the plaintiff’s increased risk of cancer was too speculative to qualify as a present injury.
The Fourth Circuit reversed, emphasizing that exposure to a toxic substance and the need for ongoing diagnostic testing constitute present, concrete harms.
The court compared the plaintiff’s claims to asbestos exposure cases, where courts have allowed recovery for medical monitoring.
The majority distinguished the case from TransUnion LLC v. Ramirez, in which future harm was insufficient to establish standing, by framing the exposure and testing costs as current injuries, Chief Judge Diaz dissented, arguing that the ruling contradicts both Supreme Court precedent and prior Fourth Circuit rulings, including Beck v. McDonald, which rejected claims based on the cost of monitoring speculative future harm.
The decision also addressed expert testimony.
The district court excluded the plaintiff’s air modeling expert under Daubert due to concerns about unreliable data and unsupported assumptions.
The Fourth Circuit reversed, ruling that such disputes concern credibility for the jury rather than admissibility. This interpretation weakens the gatekeeping role of trial courts in toxic tort cases.
If the ruling stands, plaintiffs may rely on minor exposures and medical monitoring costs to establish standing, which could broaden the scope of toxic tort litigation.
August 29, 2025: Investigation Into Cancer Risks Near Fort Myers Ethylene Oxide Plant
Concerns over toxic emissions from the American Contract Systems (ACS) facility in South Fort Myers have prompted investigations into potential cancer risks for nearby residents and workers.
The facility, which uses ethylene oxide to sterilize medical equipment, has been linked to increased risks of cancers such as thyroid cancer and lymphoma among individuals living or working within a five-mile radius since 2011.
Ethylene oxide is classified by the U.S. Environmental Protection Agency (EPA) as a human carcinogen.
The EPA first identified potential risks from the facility’s emissions in 2023.
In response, ACS installed new air-cleaning technology designed to capture nearly all emissions.
By December 2024, an EPA inspection concluded that the lifetime cancer risk from emissions had dropped below the agency’s threshold of concern, defined as less than 100 in one million.
Despite these improvements, residents continue to raise concerns about past exposure, particularly prior to the installation of emissions-control equipment.
Investigations are ongoing to determine whether individuals who lived or worked near the facility during earlier periods of higher emissions may be entitled to pursue legal claims.
Future litigation could focus on allegations of wrongful exposure, negligence, or failure to warn.
A new peer-reviewed study published in the American Journal of Industrial Medicine highlights persistent occupational overexposure to ethylene oxide (EtO) in U.S. workplaces.
Analyzing over 40 years of OSHA sampling data (1979–2020), researchers found that 46% of personal air samples collected from workers exceeded the NIOSH recommended exposure limit of 0.1 ppm.
Additionally, 18% of samples surpassed OSHA’s permissible exposure limit of 1 ppm.
The industrial sterilization sector recorded the highest levels of occupational exposure.
Approximately 70% of samples from this industry exceeded the NIOSH limit, and the sector showed minimal improvement in exposure reductions over time.
While overall workplace exposure to EtO has decreased since the 1980s, the study emphasizes wide disparities across industries.
Chemical manufacturing and health services were among the sectors with little to no post-2000 exposure data, raising concerns about underreporting and gaps in ongoing occupational health surveillance.
Given that EtO is a known human carcinogen, the study reinforces the need for updated occupational exposure monitoring and more vigorous enforcement in high-risk industries.
A federal lawsuit has been filed against Eastman Chemical Company, alleging that years of excessive ethylene oxide (EtO) emissions from its Longview, Texas, facility caused severe health consequences for local residents, including multiple breast cancer diagnoses.
The 30-page complaint, lodged in the U.S. District Court for the Eastern District of Texas, includes claims from six individuals, four of whom have developed breast cancer.
Plaintiffs argue they were unknowingly exposed to harmful levels of EtO, a toxic, odorless gas used in chemical manufacturing, while living, working, or spending significant time within miles of the industrial plant.
EtO has been classified as a “probable human carcinogen” by the U.S. Environmental Protection Agency (EPA) since 2016.
In 2018, the EPA specifically flagged the Longview area as having potentially elevated cancer risks due to emissions from the Eastman site.
According to the complaint, Eastman self-reported discharging over 565,000 pounds of EtO into the surrounding environment by 2022.
The lawsuit accuses Eastman of two counts of negligence for failing to prevent or mitigate dangerous emissions and one count of loss of consortium, brought by spouses of affected plaintiffs who claim their lives have also been harmed by the health consequences endured by their partners.
Newly uncovered documents reveal that executive administration officials blocked and revised crucial EPA warnings about the cancer risks associated with ethylene oxide, thereby delaying stricter regulations for commercial sterilizers.
The move benefited companies like Sterigenics, despite internal EPA scientists urging swift regulatory action to protect communities near sterilization facilities.
A congressional investigation released on July 18, 2024, reports that political appointees in the White House and EPA suppressed a 2020 proposal to regulate ethylene oxide emissions under the Clean Air Act.
The rule would have required commercial sterilizers to cut emissions by 80% and notify nearby residents of health risks.
After the White House Office of Information and Regulatory Affairs (OIRA) intervened, the EPA withdrew the proposed rule in its entirety.
Internal documents reveal officials altered or softened language describing ethylene oxide as “cancer-causing” and removed notices about increased cancer risks in dozens of U.S. communities.
The delay allowed industry use of the chemical with limited oversight for years, during which lawsuits over ethylene oxide exposure increased nationwide.
The findings are relevant to ongoing ethylene oxide litigation, where plaintiffs claim that long-term exposure caused cancer and other serious illnesses.
The delay in EPA regulations—and evidence of political interference—may bolster claims that companies and regulators failed to safeguard the public despite knowing the risks.
New air testing in multiple U.S. communities reveals ethylene oxide (EtO) levels much higher than previously reported by the EPA, with some readings reaching hundreds of times above the agency’s cancer risk threshold.
The Spotlight on America team collaborated with the Southwest Research Institute and utilized a mobile air lab to perform real-time monitoring near sterilization facilities.
In one Illinois neighborhood, EtO levels hit 92,000 nanograms per cubic meter—more than 300 times the EPA’s concern threshold.
The findings further undermine the trustworthiness of government air modeling, a key issue in EtO exposure lawsuits.
Plaintiffs claim that long-term exposure to EtO from medical sterilization facilities caused cancer and other serious health issues.
The new data may reinforce claims that residents were unknowingly exposed to harmful levels of EtO due to underreported emissions and insufficient federal oversight.
July 15th, 2025: Administration Weighs Pollution Exemptions in Potential Regulatory Rollbacks
Federal regulators are currently reviewing plans to allow exemptions from stringent emissions limits under the HON (Hazardous Organic NESHAP) rule, which would affect chemical plants emitting ethylene oxide (EtO) and other toxins.
The rule targets severe pollution sources and aims to reduce cancer risks for over 10 million Americans, particularly in communities near petrochemical facilities.
These proposed exemptions would permit companies to delay installation of pollution controls if compliance is deemed technologically or economically unfeasible—decisions the White House would approve.
Though specific approvals haven’t been announced, such exemptions could dramatically weaken protections for facilities known for repeated violations.
Ethylene oxide is a known carcinogen linked to blood and breast cancers and poses significant threats to communities near emitting plants.
A recent EPA analysis indicates that workers exposed to EtO in medical sterilization face up to a 1-in-10 cancer risk.
Critics warn that loosening the HON rule could lead to persistent and increased EtO exposure, especially among vulnerable populations, reversing recent public health gains.
Delaware lawmakers approved a bill last week that raises fines for environmental violations and directs those funds to communities within two miles of the pollution source.
The legislation, which is awaiting the governor’s signature, grants the state’s Department of Natural Resources and Environmental Control (DNREC) expanded authority to enforce penalties, including the power to appeal Environmental Appeals Board decisions on chronic violators.
The bill increases daily fines by up to $30,000 for certain violations, some of which hadn’t been revised in over 50 years, and creates a community-focused fund that prioritizes impacted neighborhoods over statewide initiatives.
Residents near facilities like Croda Inc.’s Atlas Point plant and the Delaware City Refinery, both with histories of violations, say the new measures are a long-overdue step toward accountability and health protections.
Environmental advocates argue that previous fines were too low to deter chronic polluters, causing DNREC to focus more on compliance than enforcement because of high appeal costs.
The Delaware State Chamber of Commerce opposed the bill, warning of increased liability and insurance costs related to what they called unjustified penalty hikes.
Communities across North Carolina are being unknowingly exposed to toxic ethylene oxide used to sterilize medical equipment.
A recent WRAL investigation found five warehouses in North Carolina storing EtO-sterilized products, including one in Four Oaks, only 1,100 feet away from residential homes.
These facilities, operated by Becton Dickinson, Owens & Minor, and Medline, continue to face minimal regulation despite releasing ethylene oxide, a recognized human carcinogen associated with breast cancer and non-Hodgkin lymphoma, even at very low exposure levels.
Unlike sterilization plants, off-site storage warehouses are not regulated by federal EtO emissions standards.
North Carolina currently does not track emissions from sterilized products, and the EPA has not yet proposed regulations to fill this gap.
Residents living near the Four Oaks warehouse have demanded greater transparency and air quality monitoring, citing health concerns for vulnerable populations.
TorHoerman Law is currently examining medical sterilization facilities across multiple states that could have exposed workers and local communities to ethylene oxide.
Our firm has a trial set for 2026 in a case concerning an individual diagnosed with cancer following long-term exposure to EtO emissions from a medical sterilization facility in the Atlanta region.
Just a few months ago, a major medical sterilization company, Steris Corporation, agreed to pay up to $48.15 million to resolve a wave of personal injury claims tied to emissions of ethylene oxide (EtO) from its former sterilization facility in Waukegan, Illinois.
The settlement, reached through its Isomedix subsidiary, aims to resolve nearly all pending lawsuits in Cook County Circuit Court involving claims of cancer and other health issues linked to EtO exposure.
The deal, disclosed in a March 2025 securities filing, comes after mounting legal and regulatory scrutiny surrounding EtO, a carcinogenic gas used to sterilize approximately half of all medical devices in the U.S.
The plaintiffs allege that emissions from the Waukegan site endangered public health between 2005 and 2008, when Steris operated the facility.
While Steris emphasized that the agreement does not admit liability or concede that emissions posed a safety risk, it agreed to the payout to resolve the cases efficiently.
The company stated it will record the settlement as a charge in its fiscal 2025 earnings but exclude it from adjusted earnings metrics.
The first EtO lawsuit against Steris ended in a mistrial earlier this year.
Now, the proposed settlement is pending court approval and hinges on a substantial majority of plaintiffs opting in.
Should those conditions not be met, Isomedix retains the right to withdraw from the agreement and continue defending itself in court.
The Environmental Protection Agency has flagged multiple EtO sterilization facilities nationwide as high cancer risk sites.
In response, it has tightened emission regulations, while medical device manufacturers and sterilization companies work to adopt safer alternatives, such as vaporized hydrogen peroxide.
Steris remains one of the world’s largest medical device sterilization providers through its Applied Sterilization Technologies unit, which absorbed the Isomedix brand.
A Georgia judge has declared a mistrial regarding punitive damages in a lawsuit that recently concluded with a $20 million compensatory award against C.R. Bard.
After a juror admitted they went along with the group without personally agreeing with the decision, the retrial will focus solely on punitive damages.
This retrial aims to hold Bard accountable for its alleged reckless disregard for public health at its sterilization plant in Covington, GA.
Plaintiff Gary Walker, a longtime resident near the facility and a former delivery driver for the site, developed non-Hodgkin’s lymphoma after prolonged exposure to ethylene oxide.
The jury initially awarded $50 million in punitive damages, but that amount was voided after the juror disclosed it.
Judge Emily Brantley confirmed that a new trial will be held to determine whether Bard should be held financially responsible beyond compensatory damages.
Under Georgia law, jurors must find intent or conscious indifference to award punitive damages; however, juries are not informed about statutory caps.
A statutory cap is a legal limit on how much money someone can receive in a lawsuit, often used to restrict payouts for things like pain and suffering or punitive damages.
Walker’s case is part of a larger trend of litigation related to toxic ethylene oxide emissions from medical sterilization facilities.
In March 2024, the EPA issued updated safety standards that included continuous emissions monitoring and more stringent controls on sterilization equipment.
Despite calls for safer alternatives, the gas continues to be widely used in the U.S. medical supply chain.
TorHoerman Law will take a Sterigenics Ethylene Oxide Exposure case to trial in Atlanta, Georgia, in March 2026.
The case involves allegations that Sterigenics, a medical sterilization company, released ethylene oxide (EtO), a known carcinogen, into the air surrounding its facility in Cobb County.
The plaintiff in the upcoming trial is a Cobb County resident who lived near the facility and was unknowingly exposed to EtO emissions over the course of several years.
The lawsuit alleges that Sterigenics failed to install proper environmental controls or emission scrubbers and vented EtO directly into a residential community.
EtO has been recognized for decades as a cancer-causing chemical.
The facility’s emissions reportedly continued without proper mitigation until within the last five years.
The lawsuit claims that Sterigenics did not notify the public of the potential dangers until after external scrutiny forced disclosure.
There were no town halls, mailers, or other efforts to inform residents prior to litigation.
Eligible claimants may include individuals who lived in the affected areas of Cobb County and later developed cancer or other serious illnesses linked to EtO exposure.
This case is part of a broader national effort to hold Sterigenics accountable for environmental contamination and resulting injuries in multiple communities.
A Georgia jury awarded $20 million on Friday to Gary Walker, a retired truck driver who claimed that exposure to ethylene oxide(EtO) from C.R. Bard’s Covington plant caused his lymphoma.
The jury found Bard liable for negligence and nuisance, concluding that punitive damages are warranted.
Thus, a second trial phase will begin on Monday, May 19.
Walker, now in remission, lived about 1.5 miles from the C.R. Bard facility starting in 1991 and made regular deliveries to the plant until retiring in 1999.
He was diagnosed with lymphoma in 2017 at the age of 68 and underwent ten rounds of chemotherapy along with a stem-cell transplant.
Walker’s legal team presented internal and regulatory documents showing that Bard had declined to implement emissions controls for decades, despite warnings from regulators and its EtO supplier, Union Carbide.
Jurors were presented with a 1985 memo from Georgia environmental officials stating that Bard “does not want to control its emissions at this time.”
In closing arguments, plaintiffs’ counsel Lindsay Forlines argued that Bard had “devices for control available” but “refused to employ them.”
The defense argued that Walker’s cancer was unrelated and stated that “no doctor ever told him that EtO had anything to do with his cancer,” according to closing statements by Eric Rumanek of Troutman Pepper Locke LLP.
This is the first EtO exposure case in Georgia to result in a plaintiff verdict, which may indicate considerable liability for Bard.
The punitive damages phase will resume on Monday, May 19, before Judge Emily Brantley.
On Tuesday, a Georgia jury began hearing claims that C.R. Bard’s medical sterilization plant in Covington exposed a resident to ethylene oxide (EtO) emissions for nearly 50 years, allegedly resulting in his cancer diagnosis.
Plaintiff Gary Walker, a retired truck driver, alleges that he developed non-Hodgkin lymphoma due to repeated occupational and residential exposure to EtO.
His attorneys informed jurors that the plant emitted nearly 10 million pounds of gas from 1970 to 2017, operated without emissions controls until 1990, and disregarded warnings from regulators and its EtO supplier, Union Carbide.
They presented a 1985 memo from Georgia officials stating that Bard “does not want to control its emissions at this time.”
Bard denies the claims and contends that Walker’s cancer resulted from a spontaneous genetic mutation unrelated to EtO.
The company adheres to regulatory standards and has implemented safety measures as federal requirements have evolved.
Defense counsel highlighted EtO’s role in sterilizing over half of all U.S. medical devices and referenced Bard’s use of safety monitoring and pollution controls.
This case marks the first exposure to ethylene oxide in Georgia to be presented before a jury.
Similar litigation is occurring in other states, following recent defense verdicts in Colorado and Pennsylvania.
Steris Corporation has agreed to pay up to $48.15 million to resolve a wave of personal injury claims tied to emissions of ethylene oxide (EtO) from its former sterilization facility in Waukegan, Illinois.
The settlement, reached through its Isomedix subsidiary, aims to resolve nearly all pending lawsuits in Cook County Circuit Court involving claims of cancer and other health issues linked to EtO exposure.
The deal, disclosed in a March 2025 securities filing, comes after mounting legal and regulatory scrutiny surrounding EtO, a carcinogenic gas used to sterilize approximately half of all medical devices in the U.S.
The plaintiffs allege that emissions from the Waukegan site endangered public health between 2005 and 2008, when Steris operated the facility.
While Steris emphasized that the agreement does not admit liability or concede that emissions posed a safety risk, it agreed to the payout to resolve the cases efficiently.
The company stated it will record the settlement as a charge in its fiscal 2025 earnings but exclude it from adjusted earnings metrics.
The first EtO lawsuit against Steris ended in a mistrial earlier this year.
Now, the proposed settlement is pending court approval and hinges on a substantial majority of plaintiffs opting in.
Should those conditions not be met, Isomedix retains the right to withdraw from the agreement and continue defending itself in court.
The Environmental Protection Agency has flagged multiple EtO sterilization facilities nationwide as high cancer risk sites.
In response, it has tightened emission regulations, while medical device manufacturers and sterilization companies work to adopt safer alternatives, such as vaporized hydrogen peroxide.
Steris remains one of the world’s largest medical device sterilization providers through its Applied Sterilization Technologies unit, which absorbed the Isomedix brand.
Braun, a German medical device manufacturer, has reached a confidential settlement to resolve the majority of lawsuits alleging that emissions from its Lehigh County, Pennsylvania facility exposed residents to toxic levels of ethylene oxide, a gas linked to cancer and neurological damage.
Dozens of lawsuits had been filed by local residents claiming that emissions from the plant caused elevated cancer risks and other serious health effects.
The plaintiffs alleged that long-term exposure to ethylene oxide—a chemical used to sterilize medical equipment—led to increased diagnoses of breast cancer, lymphoma, and other illnesses.
Though the company denies wrongdoing, B. Braun confirmed the settlement this week and stated that it will continue defending itself against any remaining claims. Details of the settlement remain confidential.
In response to the litigation and public health concerns, B. Braun noted that it installed a new emission control system in 2020 that reduced ethylene oxide emissions by more than 99.9%.
The move was made voluntarily and went beyond regulatory requirements, the company said.
The settlement comes amid a broader national reckoning over ethylene oxide use.
In March 2024, the EPA issued stricter rules for commercial sterilization facilities, including continuous air monitoring and limits on emissions during equipment start-up and shutdown.
These rules apply to approximately 90 sterilization facilities across the U.S.
The lawsuits against B. Braun are part of a growing wave of litigation targeting medical sterilization companies.
In 2023, Sterigenics agreed to a $408 million settlement over similar ethylene oxide exposure claims in Illinois, Georgia, and Michigan. Another company, Steris, is currently facing hundreds of similar lawsuits.
Although ethylene oxide is still used to sterilize about half of all U.S. medical equipment, advocates and health experts continue to call for safer alternatives.
The outcome of these cases—and increasing public scrutiny—may pressure both manufacturers and regulators to accelerate the transition to safer sterilization technologies.
Cosmed Group Inc., a medical and food sterilization company, has filed for Chapter 11 bankruptcy protection following a wave of lawsuits alleging its use of ethylene oxide (EtO) caused cancer and other serious health conditions.
The bankruptcy filing, made in Houston, Texas, comes in response to at least 300 lawsuits, including two class actions.
Plaintiffs allege exposure to ethylene oxide emissions from Cosmed facilities led to long-term health risks, particularly in surrounding communities.
Ethylene oxide is a known human carcinogen used in sterilizing medical devices and food products like spices and grains.
During a court hearing, Cosmed’s attorney David Eastlake acknowledged that litigation tied to both current and former facility operations had threatened the company’s viability.
The lawsuits span several jurisdictions and relate to alleged injuries from airborne emissions over extended periods.
Cosmed also filed alongside an affiliate, Spicey Partners Real Estate Holdings, listing more than $100 million in liabilities.
U.S. Bankruptcy Judge Christopher Lopez approved an emergency motion allowing the company to cover a $65,000 payroll for its 51 employees, while additional operational requests will be considered in future hearings.
This isn’t Cosmed’s first encounter with environmental scrutiny. In 2005, the company paid a $1.5 million settlement following a U.S. EPA probe into EtO emissions at facilities across six states.
The bankruptcy move follows similar legal pressures faced by other sterilization companies in recent years, as regulators and communities increase scrutiny over the health impact of ethylene oxide.
Cosmed has not yet announced whether it intends to pursue a global settlement as part of its Chapter 11 proceedings.
TorHoerman Law is accepting new clients for the Ethylene Oxide Exposure Lawsuit.
If you or a loved one were diagnosed with cancer or other serious health problems associated with exposure to ethylene oxide and lived near a facility with known emissions, you may be eligible to file an Ethylene Oxide Lawsuit and seek financial compensation.
Contact TorHoerman Law today for a free consultation.
Use the chat feature on this page to find out if you qualify for an Ethylene Oxide Lawsuit instantly.
Sterigenics and its parent company, Sotera Health, have agreed to a $35 million settlement to resolve a group of lawsuits alleging that emissions from the company’s Cobb County, Georgia facility caused cancer and other serious health problems.
The deal marks a pivotal moment in the growing wave of ethylene oxide litigation across the state.
The lead plaintiff in the settled case developed leukemia at the age of 20 after living for 13 years near the Sterigenics medical sterilization plant.
Filed in 2020, the plaintiff’s lawsuit argued that prolonged exposure to airborne ethylene oxide—a known carcinogen—was the likely cause of his illness.
Ethylene oxide is used to sterilize medical equipment due to its DNA-disrupting properties, but those same properties are linked to cancer in humans.
According to the CDC and NIH, the compound is associated with heightened risks of leukemia, lymphoma, and other cancers through inhalation and environmental exposure.
The plaintiff’s lawsuit, one of the first in Georgia targeting Sterigenics’ emissions, paved the way for broader legal scrutiny.
The plaintiff is now in remission and recently completed his degree from the University of Utah.
Under the terms of the conditional settlement, all plaintiffs involved must agree for the deal to take effect.
While Sterigenics and Sotera deny any wrongdoing or liability, they agreed to the payout to resolve the claims and avoid ongoing litigation.
This settlement does not resolve all outstanding legal challenges.
The companies intend to continue defending against additional personal injury and property value lawsuits, including upcoming hearings scheduled for October 2024 that will examine general causation evidence.
The $35 million agreement may influence the trajectory of other ethylene oxide cases in Georgia and nationwide, particularly as plaintiffs argue that emissions from sterilization plants pose an unacceptable public health risk.
The EPA’s Final Rule for the Synthetic Organic Chemical Manufacturing Industry (SOCMI) and polymer and resin manufacturing sectors aims to drastically reduce emissions of hazardous air pollutants, especially ethylene oxide (EtO) and chloroprene, which are both known human carcinogens.
Key Highlights of the Final Rule:
Monitoring Requirements: Facilities will be required to conduct fenceline monitoring for specific air toxics, including EtO and chloroprene, with the data made publicly accessible to inform and protect nearby communities.
After years of mounting scientific evidence and growing public alarm, the U.S. Environmental Protection Agency (EPA) is finalizing its first major update in over a decade to safety rules governing ethylene oxide (EtO)—a toxic gas linked to cancer that is used to sterilize about 50% of all medical devices in the United States.
The final rule, expected to be released by the March 1 court-ordered deadline, will establish stricter emissions limits for commercial sterilization facilities and enhanced worker safety protocols for those routinely exposed to EtO.
Mounting Health Concerns Drive Urgency
The move follows an EPA 2016 risk assessment that found EtO to be far more carcinogenic than previously understood.
The gas, already recognized by the CDC and NIH as a human carcinogen, is linked to breast cancer, non-Hodgkin lymphoma, and leukemia, among others.
Children and those living near sterilizing plants are particularly vulnerable.
Communities across the U.S., including in Laredo, TX, Covington, GA, and suburban Chicago, have rallied against nearby sterilization plants after learning they had been exposed to dangerous levels of the gas for decades—often without warning. Lawsuits and protests have followed.
One high-profile case in Georgia recently resulted in a $35 million settlement from Sterigenics and parent company Sotera, while another in Illinois awarded $363 million to a breast cancer survivor.
The finalized EPA rule is expected to include:
However, critics say the rule falls short by not requiring air monitoring around facilities or addressing EtO emissions from off-site warehouses, where sterilized products continue to off-gas.
While environmental and public health advocates view the rule as long overdue, industry groups warn of disruption.
The Advanced Medical Technology Association (AdvaMed) says companies could face over $500 million in compliance costs, potentially slowing sterilization workflows and impacting medical device availability.
The FDA has expressed concern, warning that overly restrictive rules could hinder access to essential medical supplies.
Ethylene oxide is still considered the most reliable method for sterilizing complex devices, and alternatives like steam, radiation, or hydrogen peroxide vapor are not always viable.
Sterigenics and its parent company, Sotera Health, have reached a $408 million settlement with 879 individuals who filed lawsuits alleging that emissions of ethylene oxide (EtO) from the company’s now-closed Willowbrook, Illinois facility caused cancer and other health complications.
The agreement resolves nearly all of the 882 cases pending against the company, which stemmed from the EPA’s 2018 detection of dangerously high concentrations of EtO in the air surrounding the Willowbrook site.
In 2019, the state ordered the facility closed.
Since then, the area has become one of several so-called “cancer alleys” where local residents allege long-term exposure to EtO led to serious illnesses.
EtO is a sterilizing gas used in roughly half of all U.S. medical devices.
While essential to infection control, it’s also a known human carcinogen, with chronic exposure linked to leukemia, lymphoma, breast cancer, and other conditions.
Children are considered particularly vulnerable due to EtO’s mutagenic effects on DNA.
The decision to settle follows a landmark 2022 jury verdict in which Sterigenics was ordered to pay $220 million to a single plaintiff, breast cancer survivor Susan Kamuda. Sotera and Griffith Foods, its corporate predecessor, were also hit with large penalties, pushing the total to $363 million.
The staggering award likely influenced the company’s decision to settle the rest of the Illinois claims rather than risk similar outcomes at trial.
Although Sterigenics denies wrongdoing and maintains its Willowbrook operations did not pose a safety risk, the company acknowledged the financial risk of continuing litigation.
Before taxes, the average payout per claimant under the agreement would be approximately $545,000.
Three plaintiffs opted out of the settlement and will proceed through pretrial discovery.
This resolution does not mark the end of Sterigenics’ EtO litigation.
The company still faces lawsuits in Georgia and New Mexico over similar allegations.
Additionally, new EPA regulations aimed at drastically reducing EtO emissions and greater scrutiny from both federal and state agencies suggest future legal and regulatory challenges are likely.
TorHoerman Law is accepting new clients for the Ethylene Oxide Exposure Lawsuit.
If you or a loved one were diagnosed with cancer or other serious health problems associated with exposure to ethylene oxide and lived near a facility with known emissions, you may be eligible to file an Ethylene Oxide Lawsuit and seek financial compensation.
Contact TorHoerman Law today for a free consultation.
Use the chat feature on this page to find out if you qualify for an Ethylene Oxide Lawsuit instantly.
The U.S. Environmental Protection Agency (EPA) has launched a nationwide initiative to inform communities about the health risks associated with ethylene oxide (EtO), a toxic gas used to sterilize roughly half of all U.S. medical devices.
The campaign includes updated risk data, public webinars, and community meetings for residents near nearly 100 commercial sterilization facilities.
Of these, 23 sites have been identified as posing elevated lifetime cancer risks due to long-term EtO exposure.
EPA Administrator Michael Regan emphasized the agency’s commitment to transparency and public engagement, particularly in areas with the highest risk.
EtO exposure is linked to breast cancer, leukemia, and other severe conditions.
While short-term levels don’t exceed health benchmarks, the EPA’s primary concern is cumulative, long-term exposure, especially for children and workers.
To address this, the EPA collects emissions data, reviews Clean Air Act regulations, and prepares stricter pollution control requirements for sterilization plants.
It also coordinates with the FDA to ensure that medical device availability is not compromised.
In a major step toward transparency and environmental justice, the U.S. Environmental Protection Agency (EPA) announced it is expanding Toxics Release Inventory (TRI) reporting requirements to include 29 previously unregulated sterilization facilities that use large amounts of ethylene oxide (EtO).
EtO is a known human carcinogen, with links to breast cancer, leukemia, and other severe health conditions.
The new reporting rule will also apply to ethylene glycol, a related chemical.
The EPA’s move comes after years of concerns from community advocates about undisclosed EtO emissions near residential areas, schools, and historically underserved communities.
Under the Emergency Planning and Community Right-to-Know Act (EPCRA), the EPA is using discretionary authority to mandate that these facilities report emissions and waste management data for EtO and ethylene glycol starting in 2023, based on activities tracked from January 2022.
The 29 selected facilities are among the highest EtO users in the contract sterilization sector and will likely exceed the TRI threshold of 10,000 pounds per year.
Two facilities originally considered were exempted—one no longer performs sterilization, and the other uses EtO in minimal quantities.
Ethylene oxide (EtO) is a colorless, flammable gas widely used to sterilize medical devices that cannot withstand high-temperature steam sterilization.
Despite its efficacy in sterilization, EtO is recognized as a human carcinogen by the International Agency for Research on Cancer (IARC), a division of the World Health Organization (WHO).
Chronic inhalation exposure to EtO has been linked to an increased incidence of lymphatic and hematopoietic cancers, including non-Hodgkin lymphoma, multiple myeloma, and leukemia, as well as breast cancer.
Communities residing near facilities with uncontrolled industrial emissions of EtO face elevated cancer risks due to cumulative exposure over time.

In response to these health concerns, the U.S. Environmental Protection Agency (EPA) has implemented stringent regulations to reduce EtO emissions from commercial sterilization facilities by over 90%, aiming to mitigate the associated cancer risks.
Numerous lawsuits have been filed against companies operating EtO-emitting facilities, alleging negligence in controlling emissions and failure to protect public health.
Plaintiffs seek compensation for health issues attributed to EtO exposure.
If you or a loved one have been diagnosed with breast cancer, leukemia, lymphoma, or another serious illness after living or working near a facility emitting ethylene oxide, you may be eligible to file an Ethylene Oxide Lawsuit.
TorHoerman Law is investigating claims nationwide to help affected individuals seek compensation for medical expenses, lost wages, and other damages.
Contact us today for a free case evaluation to learn more about your rights.
You can also use the chat feature on this page to find out if you’re eligible to file an Ethylene Oxide Exposure Lawsuit instantly.
Environmental exposure to ethylene oxide is a serious concern near facilities that use this chemical as a sterilizing agent for medical devices and medical equipment.
Long-term exposure to EtO emissions from these plants has been linked to an increased risk of developing breast cancer, leukemia, lymphoma, and other serious illnesses.
Residents and workers in surrounding communities may have been unknowingly exposed to hazardous levels of ethylene oxide for years.
Many lawsuits allege that companies failed to adequately control emissions or warn the public about the dangers of cumulative exposure.

Facilities Currently Under Investigation:
We are also investigating ethylene oxide exposure claims in the following states, beyond the facilities listed above:
Multiple lawsuits against Sterigenics and other medical sterilization companies have resulted in substantial financial compensation for victims affected by ethylene oxide (EtO) exposure.
One of the most notable cases involved the Sterigenics Willowbrook Facility, where residents and workers alleged that prolonged toxic exposure to EtO emissions led to increased cancer rates in the surrounding community.
In 2022, a jury awarded $363 million to a plaintiff who developed breast cancer after years of exposure from the Sterigenics Willowbrook Plant.
This verdict was followed by a 2023 global settlement of $408 million to resolve hundreds of lawsuits filed by Illinois residents.
These results demonstrate that courts recognize the serious health risks associated with EtO exposure, holding negligent companies accountable for their actions.
Notable EtO Lawsuit Results:
Human exposure to ethylene oxide has been linked to numerous adverse health effects, including an increased risk of cancer and other life-threatening illnesses.
Scientific evidence has established a strong causal association between EtO exposure and the development of lymphohematopoietic cancers, such as lymphocytic leukemia, lymphoid cancer, and non-Hodgkin lymphoma.
Communities and workers exposed to long-term EtO emissions face an elevated risk of developing breast cancer, multiple myeloma, and other malignancies.
The carcinogenic risks of EtO have been acknowledged by leading health agencies, including the World Health Organization (WHO), National Toxicology Program (a division of the National Institute of Health), and the Environmental Protection Agency (EPA).
The general population living near medical sterilization plants may have been unknowingly exposed to unsafe EtO levels for years, leading to severe health consequences.
Occupational exposure among workers handling EtO has also been tied to an increased risk of reproductive harm and immune system disorders.

Known human health effects of exposure to ethylene oxide include:
If you or a loved one have been diagnosed with cancer or other serious health conditions after prolonged exposure to EtO emissions, you may be eligible to file a lawsuit.
Contact TorHoerman Law today to discuss your legal options.
Exposed workers and communities living near facilities that emit toxic substances like ethylene oxide may experience a range of immediate and long-term health symptoms.
Respiratory irritation is one of the earliest signs of exposure, as EtO can cause inflammation and damage to the lungs.
Symptoms affecting the gastrointestinal tract, such as nausea and vomiting, have also been reported among individuals exposed to high levels of EtO.
Secondary effects of chronic exposure can include neurological issues, reproductive complications, and immune system suppression.
Many symptoms worsen with prolonged exposure, making early recognition critical for those living or working near EtO-emitting facilities.

Common symptoms of ethylene oxide (EtO) exposure include:
Extensive scientific research has established that ethylene oxide (EtO) exposure poses significant health risks to humans.
Occupational studies have demonstrated a clear association between EtO exposure and increased incidences of various cancers, particularly those affecting the lymphatic and hematopoietic systems.
Experimental animal studies have provided sufficient evidence of EtO’s carcinogenicity, reinforcing concerns about its impact on human health.
Beyond its carcinogenic properties, EtO exposure has been linked to adverse reproductive outcomes and neurological effects.
The following studies offer detailed insights into the health effects associated with EtO exposure:
Ethylene oxide (EtO) is a colorless, flammable gas with a slightly sweet odor, primarily used as a chemical intermediate in the production of ethylene glycol and other chemicals.
EtO is highly reactive and is used for its ability to penetrate various materials, making it an effective sterilizing agent.
EtO is particularly useful for sterilizing medical equipment and supplies that are sensitive to heat or moisture, such as certain plastics, electronics, and surgical instruments.
The use of EtO for sterilization dates back to the late 1950s, when it was developed as a method to ensure the sterility of medical devices without causing damage.
This method allows for the sterilization of complex and delicate instruments that cannot withstand traditional high-temperature steam sterilization.
EtO’s effectiveness against a broad spectrum of microorganisms, including bacteria, viruses, and fungi, has made it a widely adopted sterilization technique in the healthcare industry.
Despite its benefits, EtO is recognized as a human carcinogen, and exposure to it has been associated with various health risks, requiring strict regulatory controls and safety measures during its use.

Facilities utilizing EtO for sterilization are required to adhere to stringent guidelines to minimize emissions and protect both workers and surrounding communities from potential exposure.
Ongoing advancements aim to develop alternative sterilization methods; however, EtO remains a critical component in ensuring the sterility of many medical devices that cannot be effectively sterilized by other means.
Due to its classification as a human carcinogen and its potential environmental health impacts, EtO emissions are subject to stringent regulatory controls.
The U.S. Environmental Protection Agency (EPA) oversees these regulations under the Clean Air Act, aiming to mitigate toxic exposure and associated cancer risks.
In April 2024, the EPA finalized more stringent air emission standards to significantly reduce EtO emissions from commercial sterilizers, addressing concerns about uncontrolled industrial emissions and their health implications.
These regulatory actions are part of a broader effort to protect both workers and communities exposed to EtO.
The processing generally consists of implementing advanced emission control technologies and adhering to rigorous operational protocols to limit EtO release into the atmosphere.
Continuous monitoring and compliance assessments are integral components of these regulations.
Key Regulatory Actions on Ethylene Oxide Emissions:
These regulatory actions collectively aim to reduce EtO emissions, thereby protecting environmental health and minimizing the risk of cancer and other adverse effects among exposed populations.
Individuals who lived or worked near facilities emitting ethylene oxide (EtO) and have since been diagnosed with breast cancer, leukemia, lymphoma, or other serious health conditions may be eligible to file a lawsuit.
Claims are being investigated against companies responsible for toxic exposure due to uncontrolled industrial emissions, failure to implement safety measures, and misleading the public about the cancer effects of EtO.

Workers in sterilization plants, residents in high-exposure areas, and individuals with prolonged contact with EtO may have legal options.
To qualify, claimants typically need medical records confirming a diagnosis of EtO-related cancer and evidence of exposure from living or working near an affected facility.
If you’ve been exposed to ethylene oxide emissions and subsequently developed cancer or other serious health problems, you may be eligible to file an Ethylene Oxide Lawsuit.
Contact TorHoerman Law for a free consultation.
Use the chat feature on this page to find out if you’re eligible to file an Ethylene Oxide Lawsuit instantly.
Building a strong Ethylene Oxide Lawsuit requires clear evidence and documentation linking toxic exposure to cancer effects or other serious health conditions.
Plaintiffs must provide medical records, proof of residence or employment near an EtO-emitting facility, and scientific evidence demonstrating the connection between EtO and their illness.
Legal teams also rely on regulatory violations, emission reports, and expert testimony to establish liability.
Your attorney will help to gather, retain, and organize crucial evidence for your case.

Evidence in an Ethylene Oxide Lawsuit may include:
In a lawsuit, damages refer to the compensation awarded to victims for the physical, financial, and emotional losses they have suffered due to another party’s negligence.
In EtO exposure cases, individuals diagnosed with breast cancer, leukemia, lymphoma, or other serious illnesses may seek damages for medical expenses, lost wages, pain and suffering, and more.
A lawyer can help assess and calculate damages, ensuring that all economic and non-economic losses are fully accounted for in a claim.
Legal teams also consider the long-term impact of the illness, including future medical costs, disability, and diminished quality of life.

Potential damages in an Ethylene Oxide Lawsuit may include:
If you or a loved one have suffered due to EtO exposure, an experienced attorney can help you pursue the compensation you deserve.
Contact TorHoerman Law today for a free case evaluation.
TorHoerman Law is actively investigating claims from individuals diagnosed with breast cancer, leukemia, lymphoma, and other serious illnesses linked to ethylene oxide (EtO) exposure.
Communities near sterilization facilities have faced significant health risks due to toxic exposure. Companies responsible for emitting EtO have failed to protect workers and residents, and lawsuits are holding them accountable for the harm they have caused.
If you lived or worked near an EtO-emitting facility and later developed a related illness, you may be eligible to file a lawsuit and seek financial compensation.
Our legal team is committed to fighting for victims and securing compensation for medical expenses, lost wages, pain and suffering, and more.
TorHoerman Law has a proven track record in environmental and toxic exposure litigation, helping individuals and families get the justice they deserve.
We offer free case evaluations to determine whether you qualify for an Ethylene Oxide Exposure Lawsuit.
There are no upfront costs—we only get paid if we win your case.

Contact us today for a free consultation.
Use the chat feature on this page to find out if you qualify for an Ethylene Oxide Lawsuit instantly.
Individuals who lived or worked near facilities emitting ethylene oxide (EtO) and later developed cancer or other serious health conditions may qualify to file a lawsuit.
Workers in sterilization plants, residents in high-exposure areas, and others with prolonged environmental or occupational exposure to EtO may be eligible.
Common illnesses linked to EtO exposure include breast cancer, leukemia (ALL, AML, CLL, Hairy Cell Leukemia), non-Hodgkin lymphoma, multiple myeloma, and Hodgkin lymphoma.
To qualify, plaintiffs typically need medical records confirming a diagnosis, proof of residence or employment near an EtO-emitting facility, and exposure documentation.
Lawsuits claim that companies like Sterigenics and other sterilization facilities negligently emitted EtO, failed to warn communities, and ignored known carcinogenic risks.
Those who lost a loved one to EtO-related cancer may also be eligible to file a wrongful death claim.
A legal team can evaluate your case and determine whether you meet the criteria to seek compensation for medical expenses, lost wages, and other damages.
If you believe EtO exposure contributed to your illness, contact TorHoerman Law for a free case evaluation.
Yes, exposure to ethylene oxide (EtO) has been scientifically linked to an increased risk of cancer.
In 2016, the EPA classified EtO as carcinogenic to humans based on strong evidence from epidemiological studies, laboratory research, and genetic toxicity findings.
Studies have shown a positive exposure-response relationship, meaning that individuals with higher cumulative exposure levels face a greater cancer risk.
Occupational studies found increased cases of breast cancer, non-Hodgkin’s lymphoma, myeloma, and lymphocytic leukemia among exposed workers.
Laboratory tests on experimental animals confirmed carcinogenic effects, with rats and mice exposed to EtO developing lymphoid tumors and mammary carcinomas after inhalation exposure.
The EPA’s risk estimates for cancer types combined indicate that even low levels of EtO exposure can increase the likelihood of developing cancer over a lifetime.
In occupational settings, long-term exposure at 8-hour time-weighted averages (TWA) over 35 years was associated with elevated cancer risks ranging from 3.7% to 11% (upper bound estimates up to 22%).
These findings reinforce the need for strict exposure limits and legal action for individuals who have been harmed by EtO emissions from sterilization facilities.
Ethylene oxide (EtO) is highly toxic, and even short-term exposure to high concentrations can cause serious health effects.
Brief exposures to 2,500 ppm did not cause lasting effects in some individuals, but exposures above 2,000 ppm have been linked to headaches, nausea, vomiting, respiratory irritation, and hematological abnormalities.
Severe exposure levels (above 4,000 ppm for 30 minutes or 8,000 ppm for 10 minutes) can result in significant injury or death, based on animal toxicity studies.
While 500 ppm for one hour was considered unlikely to cause immediate harm, chronic exposure to much lower levels over time has been linked to an increased risk of breast cancer, leukemia, lymphoma, and other serious illnesses.
The EPA has determined that long-term exposure to even small amounts of EtO can increase cancer risk, making consistent exposure near emitting facilities a serious concern.
Individuals working in sterilization plants or living near EtO-emitting facilities should take precautions and monitor for health effects linked to prolonged exposure.
Victims of ethylene oxide (EtO) exposure may seek compensation for medical expenses, lost wages, pain and suffering, and other damages caused by toxic exposure.
Lawsuits against Sterigenics and other sterilization companies aim to hold them accountable for negligent emissions, failure to warn, and regulatory violations linked to increased cancer risks.
Plaintiffs may also pursue wrongful death claims if a loved one passed away due to EtO-related cancer or health complications.
Potential Compensation in an EtO Exposure Lawsuit:
If you or a loved one suffered health complications due to EtO exposure, you may be eligible for compensation.
Contact TorHoerman Law for a free case evaluation.
Owner & Attorney - TorHoerman Law
Here, at TorHoerman Law, we’re committed to helping victims get the justice they deserve.
Since 2009, we have successfully collected over $4 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
At TorHoerman Law, we believe that if we continue to focus on the people that we represent, and continue to be true to the people that we are – justice will always be served.
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!
In this case, we obtained a verdict of $495 Million for our client’s child who was diagnosed with Necrotizing Enterocolitis after consuming baby formula manufactured by Abbott Laboratories.
In this case, we were able to successfully recover $20 Million for our client after they suffered a Toxic Tort Injury due to chemical exposure.
In this case, we were able to successfully recover $103.8 Million for our client after they suffered a COX-2 Inhibitors Injury.
In this case, we were able to successfully recover $4 Million for our client after they suffered a Traumatic Brain Injury while at daycare.
In this case, we were able to successfully recover $2.8 Million for our client after they suffered an injury due to a Defective Heart Device.
Here, at TorHoerman Law, we’re committed to helping victims get the justice they deserve.
Since 2009, we have successfully collected over $4 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?